Key result
Colchicine cuts MACE ~33% versus placebo in coronary artery disease and reduces recurrent pericarditis.
Why the study?
Colchicine has emerged as a promising drug across cardiovascular diseases beyond pericarditis, but its overall efficacy required systematic assessment.
Does colchicine reduce cardiovascular events in patients with cardiovascular diseases?
Meta-Analysis (n=15,569)
Does colchicine reduce cardiovascular events in patients with cardiovascular diseases?
Effect estimate: RR 0.67 (95% CI 0.54-0.84)
Absolute Event Rate: 6.3% vs 9%
Colchicine is an effective anti-inflammatory agent for preventing cardiovascular events across multiple inflammatory cardiac conditions, including pericardial diseases, coronary artery disease, and atrial fibrillation.
Colchicine reduces MACE in CAD and recurrent pericarditis; confirms anti-inflammatory benefit but endpoint mismatch leaves broader use open.
Aim: Colchicine, a microtubule-disassembling (antitubulin) agent used for centuries for the treatment of gout and autoimmune diseases, is a drug of growing interest in the cardiovascular field. While in the last decades it has become cornerstone of pericarditis treatment, it has also emerged in the last few years as a promising drug in the management of coronary artery disease, atrial fibrillation and heart failure. This systematic review and meta-analysis aimed to assess the efficacy of colchicine in patients with cardiovascular diseases. Methods: Systematic search in electronic databases (MEDLINE/PubMed, Scopus, BioMed Central, the Cochrane Collaboration Database of Randomized Trials, ClinicalTrials.gov, EMBASE, Google Scholar) was performed to identify randomized controlled trials (RCTs) up to February 2021. Random-effects meta-analysis was performed to assess the risk of cardiovascular events, defined according to clinical setting. Results: Among 15,569 pooled patients from 21 RCTs, colchicine was superior to placebo in the reduction of cardiovascular events. In the setting of pericardial diseases, it was associated with a lower risk of recurrent pericarditis (17 vs 34%, RR = 0.50, 95% CI: 0.42–0.60, I2 = 10%). In other studies assessing coronary artery disease patients, colchicine was associated with a reduced risk of major adverse cardiovascular events (MACE) such as myocardial infarction, stroke, cardiovascular death, coronary revascularisation and hospitalization (6.3 vs 9%, RR = 0.67, 95% CI: 0.54–0.84, I2 = 55). Among patients with atrial fibrillation, it was associated with lower rates of recurrence (20 vs 30%, RR = 0.68, 95% CI: 0.58–0.81, I2 = 0). In the single RCT on heart failure, colchicine was not associated with improved NYHA class. Conclusion: Colchicine is a valuable anti-inflammatory agent for the prevention of cardiovascular events in patients with inflammatory cardiac conditions such as pericardial diseases, coronary artery disease and atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Casula et al. (2022) conducted a meta-analysis in Cardiovascular diseases (n=15,569). Colchicine vs. Placebo was evaluated on Major adverse cardiovascular events (MACE) in patients with coronary artery disease (RR 0.67, 95% CI 0.54-0.84). Colchicine was superior to placebo in reducing cardiovascular events, including MACE in coronary artery disease (RR 0.67; 95% CI 0.54-0.84) and recurrent pericarditis (RR 0.50).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: